PubMed Health⌕ Search

Biomedical subjects

J Parada

Publications and source records attributed to J Parada.

At least 19 recordsLinked to original sources

Formation and structure of a complex of sucrose with cobalt(III)bis(phenanthroline).

Sucrose forms a dicationic complex with cobalt(III)bis(phenanthroline) which can be isolated as the sparingly water-soluble triiodide salt or the water-soluble chloride. The circular dichroism (CD) spectrum demonstrates the Delta configuration at Co(III) and the presence of two phenanthroline and one sucrose residues in the complex. The O-2(g)--O-1(f) distance in crystalline sucrose permits strain-free coordination of these centers with Co(III) and in the complex the H-1,1'(f) singlet of sucrose separates into a pair of doublets. The 1H NMR spectrum in DMSO-d(6) shows that OH-2(g) is deprotonated and the signal of OH-1(f) is shifted strongly downfield by complexation with Co(III). Coordination involving glucose and fructose residues is consistent with neither alpha-methyl glucoside nor fructofuranose forming mixed complexes with phenanthroline. Structure simulation with the semi-empirical PM3(tm) basis set indicates that complexation by O-2(g) and OH-1(f) can give a Delta-complex with little structural distortion, whereas in hypothetical Lambda-complexes there is distortion of the sucrose residue. Observation of an NOE involving the sucrose and phenanthroline residues supports the postulated structure of the Delta-complex.

Circular Dichroism↗

Age dependency of the susceptibility of rats to aminooxyacetic acid seizures.

Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats. Highest susceptibility to AOAA seizures was observed in 7-14-day-old rat pups. The lowest susceptibility was recorded in 10-20 month-old rats. AOAA seizures in 14-day-old rats were blocked by clonazepam and valproate, but not by phenobarbital, carbamazepine, diphenylhydantoin, trimethadione or ethosuximide. Morphological analysis of brains from 14-day- and 3-month-old rats which experienced AOAA seizures did not reveal epilepsy-related damage. These observations suggest that immature rat brain is highly prone to convulsions induced by AOAA and that such convulsions are difficult to control by available antiepileptic treatment.

Aging↗

NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil.

The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline (NBQX) did not impair working memory measured as alternation behavior in the Y-maze in mice. No depressant effect on alternation was detected even when NBQX impaired locomotion measured as the total number of arm entries. Similar profile of action in the Y-shaped maze was observed after administration of an anti-ischemic drug ifenprodil. In contrast, the N-methyl-D-aspartate (NMDA) antagonist (D-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylate (D-CPPene) impaired spontaneous alternation. In the step-through passive avoidance task, mice were trained to avoid dark compartment entry. NBQX and ifenprodil did not impair learning in this task when administered before or immediately after training. In contrast, D-CPPene disturbed acquisition when administered before but not immediately after training or before retention test. These observations suggest that AMPA receptors are not critically involved in the formation of spatial working memory and acquisition (storage) in the passive avoidance, and have no effect on recall (retrieval) from long-term memory.

Animals↗

Dopaminergic modulation of aldosterone secretion in the normal menstrual cycle.

A group of eight normotensive female volunteers with regular menstrual cycles were studied during two menstrual cycles: a control cycle and one in which they received lisuride, a D1-D2 dopamine agonist (0.025 mg/8 hr). The following tests were performed in both halves of both cycles: 1) the response of prolactin (PRL) to thyrotropin-releasing hormone (TRH) administration; 2) the response of plasma renin activity (PRA) and plasma aldosterone (PA) to furosemide for 2 hours in the upright posture; and 3) the response of PRL, PRA, PA, plasma potassium (K), and cortisol (F) to metoclopramide administration. An increased response of PRL to TRH and PA to furosemide in the upright position and to metoclopramide were found in the luteal phase of the control study (p less than 0.05). After lisuride administration, in the interphase, differences in the responses of PRL to TRH and PA to furosemide in the upright position disappeared, whereas that of PA to metoclopramide increased further. We conclude that the increase of aldosterone normally observed during the luteal phase of the menstrual cycle is at least partly conditioned by diminished dopaminergic tone and that the response of aldosterone secretion to furosemide-induced sodium depletion and its response to metoclopramide stimulation may be modulated by two different types of dopamine receptors.

Adult↗

Effect of ZK 36 374 on blood pressure, diuresis, plasma renin activity and urinary excretion of prostaglandin E2 and sodium.

ZK 36 374 is a chemically stable prostacyclin analogue which has been demonstrated to be a potent vasodilator. The effects of the drug on blood pressure, plasma renin activity, diuresis and urinary excretion of prostaglandin E2 and sodium, were studied on the 1st and 7th days of treatment and a week after the end of the administration to rats submitted to the following experimental situations: Goldblatt 2k-1c, Goldblatt 2k-1c + 5% NaCl loading, 5% NaCl loading, and controls. ZK 36 374 was continuously administered during one week by an osmotic pump subcutaneously implanted and connected to the right jugular vein. Twenty four hours after the pump implantation, blood pressure decreased in the three experimental groups. At the 7th day, pressure remained at similar levels except in NaCl loaded rats where an increase was observed. At the 15th day pressure levels returned to pretreatment values. On the 7th day of treatment urinary PGE2 showed higher values than pretreatment ones, to return to pretreatment at the 15 day. Sodium excretion showed an increase on the 7th day and was even higher on the 15th day. Plasma renin activity levels remained unchanged during the treatment except in the Goldblatt 2k-1c group which showed a significant fall at the 7th day. All the changes described on the 1st day of treatment might be related to counteraction of the blood pressure decrease on the same day.

Animals↗

Dopamine control of aldosterone secretion in end-stage renal failure.

The role of the tonic inhibitory effect of dopamine on aldosterone secretion has been investigated in 10 patients with chronic renal failure (CRF) on hemodialysis, in 8 normotensive renal transplant recipients (Tx) with normal renal function and in 8 normotensive volunteers (NV). The following tests were performed: the response of plasma aldosterone (PA) to metoclopramide administration; the response of plasma prolactin (PRL) to TRH administration, and the changes induced by Lisuride (a dopaminergic agonist, on the values of PA and PRL). The basal values of PA and PRL were higher in CRF than in NV and Tx. The inverse was true for plasma renin activity (PRA) values. The response of PA and PRL to metoclopramide showed blunted increases in CRF when compared to NV, in the absence of changes of PRA, cortisol and potassium. After TRH administration, PRL increase in CRF was also inferior. Lisuride induced a decrease of both PA and PRL both in CRF and NV. In Tx, basal values of PA and PRL were similar to NV. Nevertheless, the response to metoclopramide and TRH were partially blunted when compared to that of NV. These results point to the existence of a deranged dopaminergic regulation of aldosterone secretion in end-stage renal failure patients. The alterations are partially corrected by a well-functioning kidney graft.

Adult↗

Influence of lisuride, a dopaminergic agonist, on the sexual function of male patients with chronic renal failure.

The effects of Lisuride, a dopaminergic agonist, on the levels of plasma prolactin (PRL), testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and on the variations of libido and coital frequency of patients with chronic renal failure (CRF) have been investigated in a group of 20 male patients (ten normoprolactinemic and ten hyperprolactinemic). Ten patients were included in a hemodialysis program and another ten received conservation therapy (all had creatinine clearance rates below 15 mL/min). The response of PRL to TRH administration and that of LH and FSH to LH-RH administration have also been studied. Low levels of plasma testosterone found initially in all the patients, increased in both normoprolactinemic (P less than 0.05) and hyperprolactinemic patients (P less than 0.01) during Lisuride administration. PRL decreased (P less than 0.01) in both groups during therapy. The increase of plasma testosterone was greater in hyperprolactinemic patients (86% v 15% in normoprolactinemic) and was accompanied by a clear improvement in the studied parameters of sexual behaviors. The response of PRL to TRH was modified in hyperprolactinemic patients while that of LH and FSH to LH-RH was not modified, although Lisuride induced an increase of the basal value of LH (P less than 0.01) in the hyperprolactinemic group. The drug was fairly well tolerated, did not induce hypotension, and the overall incidence of side effects decreased along the study. These results stress the need for further studies with this agent in patients with chronic renal failure and sexual dysfunction.

Adult↗

The 24-hour control of blood pressure in hypertension of chronic renal disease with mepindolol.

The efficacy of mepindolol in the control of blood pressure during 24 hours was investigated in nine patients with hypertension accompanying chronic renal disease. The patients were classified into three groups having glomerular filtration rates of 50% to 55%, 30% to 35%, and 10% to 15%. The daily dosage of mepindolol was 5 mg for patients with glomerular filtration rates 30% and higher and 2.5 and 1.25 mg for patients with more advanced renal failure. The control of blood pressure was adequate in patients treated with 5 mg. In those with advanced renal failure, 2.5 mg was adequate to control blood pressure, but 1.25 mg was an inadequate dosage. These results point to the efficacy of mepindolol in the treatment of hypertension of chronic renal disease. Moreover, the dosage of the beta-blocker can be reduced by half the recommended dosage when advanced renal failure is present.

Adult↗